Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience
about
Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cellsThe role of age on dose-limiting toxicities in phase I dose-escalation trials.Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events.
P2860
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@ast
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@en
type
label
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@ast
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@en
prefLabel
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@ast
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@en
P2093
P2860
P356
P1433
P1476
Risk of serious toxicity in 11 ...... erson Cancer Center experience
@en
P2093
G S Falchook
J J Wheler
R Kurzrock
P2860
P304
P356
10.1093/ANNONC/MDS027
P577
2012-02-29T00:00:00Z